Version 1
: Received: 9 September 2024 / Approved: 9 September 2024 / Online: 9 September 2024 (13:19:01 CEST)
How to cite:
Strojan, P.; Plavc, G.; Šifrer, R.; Jereb, S.; Lanišnik, B.; Kokalj, M.; Grošelj, A.; Grašič Kuhar, C. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Larynx Preservation in Laryngeal and Hypopharyngeal Cancer. Preprints2024, 2024090697. https://doi.org/10.20944/preprints202409.0697.v1
Strojan, P.; Plavc, G.; Šifrer, R.; Jereb, S.; Lanišnik, B.; Kokalj, M.; Grošelj, A.; Grašič Kuhar, C. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Larynx Preservation in Laryngeal and Hypopharyngeal Cancer. Preprints 2024, 2024090697. https://doi.org/10.20944/preprints202409.0697.v1
Strojan, P.; Plavc, G.; Šifrer, R.; Jereb, S.; Lanišnik, B.; Kokalj, M.; Grošelj, A.; Grašič Kuhar, C. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Larynx Preservation in Laryngeal and Hypopharyngeal Cancer. Preprints2024, 2024090697. https://doi.org/10.20944/preprints202409.0697.v1
APA Style
Strojan, P., Plavc, G., Šifrer, R., Jereb, S., Lanišnik, B., Kokalj, M., Grošelj, A., & Grašič Kuhar, C. (2024). Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Larynx Preservation in Laryngeal and Hypopharyngeal Cancer. Preprints. https://doi.org/10.20944/preprints202409.0697.v1
Chicago/Turabian Style
Strojan, P., Ales Grošelj and Cvetka Grašič Kuhar. 2024 "Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Larynx Preservation in Laryngeal and Hypopharyngeal Cancer" Preprints. https://doi.org/10.20944/preprints202409.0697.v1
Abstract
Background/Objectives: To test the hypothesis that clinical tumor response after a single cycle of induction chemotherapy (ICT) can reliably differentiate between chemo-/radiosensitive and resistant tumors in the larynx preservation setting. Methods: Treatment consisted of docetaxel/cisplatin/5-fluorouracil (TPF) ICT followed by concurrent chemoradiotherapy (cCRT) with weekly cisplatin. The response of the primary tumor was assessed by transnasal endoscopy after the first ICT cycle. Results: 37/39 (95%) patients with laryngeal (46%) or hypopharyngeal (54%) carcinoma responded to one cycle of ICT, and two patients were referred for salvage surgery. Laryngectomy-free survival at 2 and 5 years was 87% and 75%, respectively. The corresponding rates for locoregional control (and also for disease-free survival) were 79% and 70% and for overall survival 92% and 82%. Conclusions: Clinical assessment of tumor response to one cycle of TPF ICT serves as a valid and easy-to-use predictor of tumor sensitivity to platinum-based cCRT.
Keywords
induction chemotherapy; response; organ preservation; laryngeal cancer; hypopharyngeal cancer
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
